December 2025 | Hematology, Transfusion and Cell Therapy

CASE REPORT: WIDESPREAD BONE INVOLVEMENT AFTER ALLOGENEIC TRANSPLANTATION IN A PATIENT WITH BIPHENOTYPIC ACUTE LEUKEMIA

Yakup ÜNSAL, Muhammed MURATI, Güler DELİBALTA, Serdar Bedii OMAY

Hematol Transfus Cell Ther. 2025;47 Supl 4:106173

Full text access

Share

“Kappa Light-Chain Multiple Myeloma Without Serum M-Spike: A Diagnostic and Therapeutic Challenge in an Elderly Patient”

Birol Güvenç

Hematol Transfus Cell Ther. 2025;47 Supl 4:106174

Full text access

Share

Early-Stage Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL) in a Young Woman: A Rare Subtype Managed Without Chemotherapy

Birol Güvenç

Hematol Transfus Cell Ther. 2025;47 Supl 4:106175

Full text access

Share

GLYCEMIC CONTROL, RENAL FUNCTION, AND HEMATOLOGICAL PARAMETERS: A RETROSPECTIVE REAL-WORLD ANALYSIS

Melike Saday Bozkurt, Ali Turunç

Hematol Transfus Cell Ther. 2025;47 Supl 4:106176

Full text access

Share

POEMS SYNDROME: CLINICAL FEATURES, DIAGNOSIS, AND TREATMENT APPROACHES

Serkan Güven

Hematol Transfus Cell Ther. 2025;47 Supl 4:106178

Full text access

Share

UPDATES ON TARGETED THERAPIES IN ACUTE MYELOID LEUKEMIA

Ufuk Demirci

Hematol Transfus Cell Ther. 2025;47 Supl 4:106179

Full text access

Share

OLD TRADITIONS IN A NEW VILLAGE*… WHY ARE FACTORS STILL NECESSARY? CONTEMPORARY PARADİGMS İN HEMOPHILIA MANAGEMENT AND THE IRREPLACEABLE ROLE OF FACTOR REPLACEMENT

Bariş Yılmaz

Hematol Transfus Cell Ther. 2025;47 Supl 4:106180

Full text access

Share

IRON CHELATİON İN MYELODYSPLASTİC SYNDROMES: WHO AND WHEN?

Hande Oğul Sücüllü

Hematol Transfus Cell Ther. 2025;47 Supl 4:106181

Full text access

Share

THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)

Emel İşleyen Kaya

Hematol Transfus Cell Ther. 2025;47 Supl 4:106182

Full text access

Share

THE TREATMENT ALGORITHM FOR SICKLE CELL DISEASE

Metin Çil

Hematol Transfus Cell Ther. 2025;47 Supl 4:106183

Full text access

Share

WALDENSTRÖM MACROGLOBULINEMIA

Zekeriya Aksöz

Hematol Transfus Cell Ther. 2025;47 Supl 4:106184

Full text access

Share

REFRACTORY CHRONIC MYELOID LEUKEMIA: A REVIEW OF CURRENT THERAPEUTIC LANDSCAPE AND EMERGING CHALLENGES

DENİZ ÖZMEN

Hematol Transfus Cell Ther. 2025;47 Supl 4:106185

Full text access

Share

HYPERCOAGULABILITY: ETIOLOGY, DIAGNOSIS AND TREATMENT PRINCIPLES

Tanju Atamer

Hematol Transfus Cell Ther. 2025;47 Supl 4:106186

Full text access

Share

THE PLACE OF IMMUNOTHERAPY IN ALL

Mehmet Bakırtaş

Hematol Transfus Cell Ther. 2025;47 Supl 4:106187

Full text access

Share

DIAGNOSIS AND MANAGEMENT OF EOSINOPHILIA

Esra Cengiz

Hematol Transfus Cell Ther. 2025;47 Supl 4:106188

Full text access

Share

TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA: CURRENT EVIDENCE, PREDICTORS, AND FUTURE DIRECTIONS

Yunus Çatma

Hematol Transfus Cell Ther. 2025;47 Supl 4:106189

Full text access

Share

THE PAST, PRESENT, AND FUTURE OF TRANSFUSION

Mahmut Bayık

Hematol Transfus Cell Ther. 2025;47 Supl 4:106190

Full text access

Share

PLATELET FUNCTION DISORDERS: CONTEMPORARY INSIGHTS AND FUTURE DIRECTIONS

Salih Sertaç Durusoy

Hematol Transfus Cell Ther. 2025;47 Supl 4:106191

Full text access

Share

CNS INVOLVEMENT IN PRIMARY AND SECONDARY ALL AND TREATMENT STRATEGIES

Sultan Okur Acar

Hematol Transfus Cell Ther. 2025;47 Supl 4:106192

Full text access

Share

YEŞİM OYMAK

Hematol Transfus Cell Ther. 2025;47 Supl 4:106193

Full text access

Share

OPTIMIZATION OF TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA

Nanişe Gizem Fener

Hematol Transfus Cell Ther. 2025;47 Supl 4:106194

Full text access

Share

Filiz Yavaşoğlu

Hematol Transfus Cell Ther. 2025;47 Supl 4:106195

Full text access

Share

INNOVATIVE TREATMENTS FOR MYELOFIBROSIS

Aysu Timuroğlu

Hematol Transfus Cell Ther. 2025;47 Supl 4:106196

Full text access

Share

CURRENT TREATMENT APPROACHES IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA

Fatma Arikan

Hematol Transfus Cell Ther. 2025;47 Supl 4:106197

Full text access

Share

HEPATIC VENO-OCCLUSIVE DISEASE

Barbaros Şahin Karagün

Hematol Transfus Cell Ther. 2025;47 Supl 4:106198

Full text access

Share

TREATMENT OF RELAPSED/REFRACTORY DLBCL

Hakan Kalyon

Hematol Transfus Cell Ther. 2025;47 Supl 4:106199

Full text access

Share

MODULATION OF INEFFECTIVE ERYTHROPOIESIS IN THALASSEMIA

Şifa Şahin

Hematol Transfus Cell Ther. 2025;47 Supl 4:106200

Full text access

Share

STEM CELL MOBILIZATION: AUTOLOGOUS AND ALLOGENEIC

Gülsüm Akgün Çağlıyan

Hematol Transfus Cell Ther. 2025;47 Supl 4:106201

Full text access

Share

LABORATORY EVALUATION IN MYELOMA: WHICH TESTS SHOULD BE PREFERRED DURING DIAGNOSIS AND FOLLOW-UP?

Burcu Altındağ Avcı

Hematol Transfus Cell Ther. 2025;47 Supl 4:106202

Full text access

Share

ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE: INSIGHTS INTO ETIOPATHOGENESIS

Mahmut Bakır Koyuncu

Hematol Transfus Cell Ther. 2025;47 Supl 4:106203

Full text access

Share

CHELATION THERAPY IN THALASSEMIA

Utku Aygüneş

Hematol Transfus Cell Ther. 2025;47 Supl 4:106204

Full text access

Share

RELAPS/REFRACTORY MANTLE CELL LYMPHOMA TREATMENT

Damla Ortaboz

Hematol Transfus Cell Ther. 2025;47 Supl 4:106205

Full text access

Share

SUMMARY: OPTIMIZATION OF TREATMENT IN PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL)

Demet Çekdemir

Hematol Transfus Cell Ther. 2025;47 Supl 4:106206

Full text access

Share

CRS AND ICANS MANAGEMENT

Mehmet Gündüz

Hematol Transfus Cell Ther. 2025;47 Supl 4:106207

Full text access

Share

GRAFT VERSUS HOST DISEASE PROPHYLAXIS

Şebnem İzmir Güner

Hematol Transfus Cell Ther. 2025;47 Supl 4:106208

Full text access

Share

CHRONİC LYMPHOCYTIC LEUKEMIA (CLL): IMMUNOGENETICS AND DIAGNOSIS

Meryem Şener

Hematol Transfus Cell Ther. 2025;47 Supl 4:106209

Full text access

Share

INTERPRETATION OF GENETIC TESTING IN CHRONIC MYELOPROLIFERATIVE NEOPLASMS

Selver Kurt

Hematol Transfus Cell Ther. 2025;47 Supl 4:106210

Full text access

Share

ATYPICAL HEMOLYTIC UREMIC SYNDROME: FROM PATHOPHYSIOLOGY TO THERAPEUTIC ADVANCES

Mustafa Duran

Hematol Transfus Cell Ther. 2025;47 Supl 4:106211

Full text access

Share

CURATIVE TREATMENT APPROACHES IN THALASSEMIA

Ömer Doğru

Hematol Transfus Cell Ther. 2025;47 Supl 4:106212

Full text access

Share

NON-FACTOR APPROACHES AND NEW HORIZONS

Nurgül Yönyül

Hematol Transfus Cell Ther. 2025;47 Supl 4:106213

Full text access

Share

IMMUNE THROMBOCYTOPENİA: PATHOPHYSIOLOGY AND MOLECULAR BIOLOGY

Kübra Yel Uygun

Hematol Transfus Cell Ther. 2025;47 Supl 4:106214

Full text access

Share

HIGH-RISK MDS TREATMENT AND INNOVATIONS

Mehmet Çelik

Hematol Transfus Cell Ther. 2025;47 Supl 4:106215

Full text access

Share

CURATIVE TREATMENT OPTIONS IN SICKLE CELL DISEASE

Merve Yahşi

Hematol Transfus Cell Ther. 2025;47 Supl 4:106216

Full text access

Share

DİAGNOSİS AND TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBİNURİA

Tahsin Yüksel

Hematol Transfus Cell Ther. 2025;47 Supl 4:106217

Full text access

Share

ALL IN ADOLESCENT AND YOUNG ADULTS

Mesut Tahta

Hematol Transfus Cell Ther. 2025;47 Supl 4:106218

Full text access

Share

WHY I CHOSE HEMATOLOGY ?

Emin Kansu

Hematol Transfus Cell Ther. 2025;47 Supl 4:106219

Full text access

Share

DONOR SELECTION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

İbrahim Eker

Hematol Transfus Cell Ther. 2025;47 Supl 4:106220

Full text access

Share

GENE THERAPY IN HEMOPHILIA

Assoc. Prof. Dr. Nihal Karadaş

Hematol Transfus Cell Ther. 2025;47 Supl 4:106221

Full text access

Share